Paijin Biopharm

Paijin Biopharm is a clinical-stage biopharmaceutical company based in Beijing, China, specializing in the development of high-end biosimilars and innovative recombinant protein drugs. The company leverages its proprietary PEGylation technology and advanced protein expression platforms to create long-acting therapeutics for metabolic diseases, oncology, and ophthalmology. Its robust pipeline includes long-acting versions of growth hormone, interferon, and GLP-1 receptor agonists, as well as biosimilars for blockbuster drugs like Semaglutide and Aflibercept. Paijin Biopharm aims to provide affordable, high-quality biological medicines to the global market through its integrated R&D and manufacturing capabilities.